文献速递甲状腺疾病

甲状腺髓样癌:单一机构30年经验及复发危险因素

Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该回顾性研究分析了1990至2023年单中心68例接受手术的甲状腺髓样癌患者,复发率为22%,中位随访4.7年。男性、侧颈淋巴结阳性及高/最高风险RET突变与复发显著相关,术前降钙素>2175 pg/mL提示远处转移,手术范围与复发无显著关联。

要点

  • 男性、侧颈淋巴结阳性、高/最高风险RET突变与复发显著相关。
  • 术前降钙素>2175 pg/mL是远处转移的强预测指标(AUC 0.893)。
  • 手术范围与复发无显著关联(P = .634)。

核心结论

  • 约四分之一接受手术的甲状腺髓样癌患者会复发。
  • 与复发相关的危险因素为男性、侧颈淋巴结转移及高/最高风险水平RET突变,而不一定是手术类型。
  • 术前降钙素>2175 pg/mL提示晚期疾病,应促使进一步评估。

研究设计与样本

  • 回顾性病历审查,1990年至2023年在单一专科三级转诊中心进行。
  • 纳入68例接受手术的甲状腺髓样癌患者,采用描述性分析和回归模型。

主要发现

  • 诊断时平均年龄54.9岁(42.2-64.1),女性占65%(n = 44)。
  • 淋巴结转移和远处转移分别占24%(n = 16)和4%(n = 3)。
  • RET突变存在于52%(n = 35)的患者中:最高风险6%,高风险7%,中风险39%。
  • 平均肿瘤大小1.9 cm(1.2-3.2),术前平均降钙素504.4 pg/mL(133.2-1833.8)。
  • 全甲状腺切除术10例,全甲状腺切除+中央颈淋巴结清扫28例,全甲状腺切除+中央及侧颈淋巴结清扫25例;最终病理中央淋巴结阳性40%,侧颈淋巴结阳性25%;复发率22%,中位随访4.7年(1.2-28.0)。

关键数值与推荐

  • 男性与复发显著相关(HR 5.81,P = .021)。
  • 侧颈淋巴结阳性与复发显著相关(HR 8.10,P = .011)。
  • 高/最高风险水平RET突变与复发显著相关(HR 8.66,P = .004)。
  • 术前降钙素>2175 pg/mL对远处转移有强预测价值(AUC 0.893),对侧颈病变有较好预测价值(AUC 0.706)。
  • 手术范围与复发无显著关联(P = .634)。

临床怎么用

  • 对于甲状腺髓样癌术后患者,男性、侧颈淋巴结转移及高/最高风险RET突变者需关注复发风险。
  • 术前降钙素>2175 pg/mL提示晚期疾病,应促使进一步评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Medullary thyroid cancer (MTC) has a historic recurrence rate up to 50%, and surgery remains the only cure. OBJECTIVE: This study aims to assess factors related to recurrence and metastatic spread in MTC. METHODS: Retrospective chart review was performed from 1990 to 2023 at a single specialized tertiary care referral center. Descriptive analysis and regression models were used for analysis. Sixty-eight patients with MTC, who underwent surgery, were included and the main outcome measure was recurrence. RESULTS: Mean age at diagnosis was 54.9 years (42.2-64.1), 65% (n = 44) females. Lymph node and distant metastases were found in 24% (n = 16) and 4% (n = 3), respectively. RET mutations were present in 52% (n = 35): MTC risk levels were highest 6%, high 7%, and moderate 39%. Mean tumor size was 1.9 cm (1.2-3.2) and mean preoperative calcitonin was 504.4 pg/mL (133.2-1833.8). Total thyroidectomy (TT) was performed in 10 patients, TT + central neck dissection (CND) in 28, and TT + CND + lateral neck dissection (LND) in 25. On final pathology, 40% had positive central nodes and 25% had positive lateral nodes. Recurrence was 22%, median follow-up 4.7 years (1.2-28.0). Male gender (hazard ratio [HR] 5.81, P = .021), positive lateral neck nodes (HR 8.10, P = .011), and high/highest MTC risk level RET mutations (HR 8.66, P = .004) were significantly associated with recurrence. Preoperative calcitonin >2175 pg/mL was a strong predictor for distant metastasis (area under the curve [AUC] 0.893) and a good predictor for lateral neck disease (AUC 0.706). Extent of surgery was not significantly associated with recurrence (P = .634). CONCLUSION: One of 4 patients undergoing surgery for MTC will recur. Risk factors associated with recurrence are male gender, lateral lymph node metastasis, and high/highest MTC risk level mutations, but not necessarily surgery type. Preoperative calcitonin >2175 pg/mL is suggestive of advanced disease and should prompt further evaluation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Abou Azar S, Tobias J, Applewhite M, et al. Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence. J Clin Endocrinol Metab. 2024. PMID: 38651609. doi:10.1210/clinem/dgae279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。